About 1,700 searches a month ask how creatine and ADHD relate — most of them "creatine adhd", a third of them "creatine and Adderall". Two different questions sit behind those words: whether creatine might help attention, and whether it is safe to combine with a stimulant. The evidence answers both the same way: nobody has tested it.
This page sets out what has been studied instead, with the searches stated so they can be repeated, and what the medicines' own labels say. It reports; it does not advise. Anyone taking ADHD medication should take the supplement question to the prescriber.
No trial in people with ADHD
- PubMed, 2026-10-26:
creatine[tiab] AND (ADHD[tiab] OR "attention deficit"[tiab] OR "attention-deficit"[tiab])→ 78 records. None is a trial that gave creatine to people with ADHD and measured ADHD outcomes. A narrower search, creatine in the title plus supplement or monohydrate, returns 3 records — a 1993 review of creatine deficiency disorders, an oxygen-deprivation study in healthy adults, and a treatment report in creatine transporter deficiency. - ClinicalTrials.gov, 2026-10-26: condition ADHD, intervention creatine → 0 studies, at any stage.
So the question searchers are asking has no direct answer. The 78 records are about other things, and it is worth seeing what.
Why the word appears so often: creatine as a ruler
Most of those 78 papers are magnetic resonance spectroscopy studies — brain scans that measure chemicals such as glutamate, N-acetylaspartate and choline in a small region. Absolute amounts are hard to measure, so these studies report each chemical as a ratio to creatine, which is assumed to be stable. A typical example is a 12-week trial of long-acting methylphenidate in school-age children that reported changes in Glu/Cr, NAA/Cr, Cho/Cr and mI/Cr in the prefrontal cortex (PMID 22318191). The treatment was the stimulant; creatine was the denominator.
That matters because headlines and supplement pages sometimes cite these scans as evidence of "creatine changes in ADHD". In most of them, a change in a ratio says nothing about creatine as such, and none tested a creatine supplement.
The link that is real, and narrow
Creatine transporter deficiency is a rare X-linked genetic disorder in which creatine cannot get into brain cells, causing intellectual disability, speech delay and seizures; it is described on creatine transporter deficiency. A Cincinnati team writing in 2020 noted that "a significant portion" of people with the disorder are diagnosed with ADHD, and found that mice lacking the transporter only in their dopamine-producing neurons were hyperactive from 3 to 12 months of age while their motor function was spared (Abdulla 2020, PMID 31520365).
Three limits keep this from being a case for supplements:
- In the disorder, the transporter is broken, so creatine taken by mouth reaches the brain poorly; in classic male cases supplementation has generally not restored brain creatine (creatine transporter deficiency sets out what has been tried).
- The mouse finding is about creatine being absent from a set of neurons, not about adding more to a normally supplied brain.
- In the spontaneously hypertensive rat, an established animal model of ADHD, rats with higher frontal-lobe creatine showed more hyperactivity in a familiar setting (Liso Navarro 2014, PMID 24855038) — the opposite direction to the supplement story.
One more animal finding is sometimes cited: methylphenidate given to young and adult rats raised creatine kinase activity in several brain regions (Scaini 2008, PMID 18938183). Creatine kinase is the enzyme that recycles creatine's energy, not creatine itself (creatine kinase explains the difference); the study did not test creatine.
Attention in people without ADHD
The nearest human evidence is in adults who do not have ADHD.
- Xu 2024, a meta-analysis of 16 randomised trials, 492 participants aged 21–76, found creatine monohydrate improved memory (SMD 0.31, moderate certainty) and shortened attention time (SMD −0.31), but the attention result was graded low certainty, and there was no effect on overall cognitive or executive function (PMID 39070254).
- EFSA 2024. Assessing an application from AlzChem, the European Food Safety Authority's nutrition panel weighed 23 human studies and concluded that a cause-and-effect relationship between creatine and improved cognitive function had not been established; the working-memory effect appeared at 20 g a day for 5–7 days and not at lower amounts (PMID 39564533).
Neither enrolled people with ADHD, and an attention-time task in a lab is not an ADHD rating scale. The wider set of brain claims is on creatine and brain claims and the full ledger on cognitive claims.
Creatine and Adderall: what the labels say
There is no study of creatine taken with amphetamine, methylphenidate or atomoxetine. The other public source is the medicines' own labelling, so it was searched:
| openFDA drug-label records, 2026-10-26 | Records | Records containing "creatine" |
|---|---|---|
| Amphetamine (incl. Adderall-type mixed salts) | 74 | 0 |
| Methylphenidate | 79 | 0 |
| Lisdexamfetamine | 27 | 0 |
| Atomoxetine | 48 | 0 |
No interaction is listed. That is a documented absence: labels list interactions that have been studied or reported, and nobody has studied this one.
Two neighbouring facts are on record. Amphetamines have case reports of rhabdomyolysis — severe muscle breakdown with very high creatine kinase — one at a low dose and one alongside several other risk factors (PMID 36046308; PMID 23276898); neither names a creatine supplement. And creatine itself shifts a blood marker: it raises creatinine, which can look like a kidney result in a routine blood test (what creatine does to bloodwork). Both are reasons the prescriber should know about any supplement, not findings about this combination.
The FDA's adverse-event reports
The FDA's food and supplement adverse-event database (CAERS) held 210 reports naming a product with "creatine" in its brand name on 2026-10-26. One lists "disturbance in attention" — a 2016 report naming a creatine powder alongside a tribulus capsule and a testosterone-support product. A report records that something happened after use; it does not establish cause. Reports of anxiety and agitation are counted separately on creatine and anxiety.
What is not established
- Whether creatine changes ADHD symptoms in children or adults — never tested.
- Whether creatine interacts with any ADHD medicine — never tested, and not on any label searched.
- Whether brain creatine is low in ordinary ADHD — the scan literature mostly uses creatine as a reference and cannot answer it; the animal results point in both directions.
- Whether the small attention-time effect in healthy adults is real — low certainty on its own meta-analysis, and not accepted by EFSA.
What a supplement does or does not do for a diagnosed condition, and whether to add one to a prescription, is a question for the prescribing clinician. This page reports what has been studied; it does not tell anyone what to take.
Sources
- PubMed searches run 2026-10-26 (queries stated above), via NCBI E-utilities.
- ClinicalTrials.gov API v2, condition ADHD + intervention creatine, 2026-10-26: 0 studies.
- openFDA drug label endpoint,
openfda.generic_nameamphetamine / methylphenidate / lisdexamfetamine / atomoxetine, with and without "creatine", 2026-10-26. - openFDA food/event endpoint (CAERS),
products.name_brand:creatine, 210 reports, 2026-10-26. - Abdulla ZI, et al. Deletion of the creatine transporter (Slc6a8) in dopaminergic neurons leads to hyperactivity in mice. J Mol Neurosci 2020. PMID 31520365.
- Liso Navarro AA, et al. Effect of diet on brain metabolites and behavior in spontaneously hypertensive rats. Behav Brain Res 2014. PMID 24855038.
- Scaini G, et al. Methylphenidate increases creatine kinase activity in the brain of young and adult rats. Life Sci 2008. PMID 18938183.
- Effect of 12-week administration of long-acting methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr and mI/Cr ratios. Clin Neuropharmacol 2012. PMID 22318191.
- Xu C, et al. Front Nutr 2024. PMID 39070254.
- EFSA NDA Panel. EFSA Journal 2024;22(11):e9100. PMID 39564533.
- Rhabdomyolysis case reports with amphetamines: Cureus 2022 PMID 36046308; Am J Med Sci 2013 PMID 23276898.